Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome

Aurelio Negro, Giovanni M. Rossi, Davide Nicoli, Annibale Versari, Enrico Farnetti, Rosaria Santi, Stefano De Pietri

Research output: Contribution to journalArticlepeer-review


Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.

Original languageEnglish
JournalAmerican Journal of Kidney Diseases
Publication statusAccepted/In press - 2017


  • 177-Lu-DOTATATE
  • Cancer
  • Case report
  • Gitelman
  • Hypocalcemia
  • Hypokalemia
  • Hypomagnesemia
  • Nephrotoxicity
  • Neuroendocrine tumors (NETs)
  • Peptide receptor radionuclide therapy (PRRT)
  • Radiometabolic
  • Tubulopathy
  • Urine electrolytes

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome'. Together they form a unique fingerprint.

Cite this